Pegloxenatide

Pegloxenatide (Polyethylene glycol loxenatide) is a long-acting glucagon-like peptide-1 receptor (GLP-1RA) agonist. Pegloxenatide has various activities such as lowering blood glucose, lowering blood lipids, improving body weight, anti-inflammation, promoting wound healing, protecting the liver, and protecting the heart. Pegloxenatide can be used in the research of type 2 diabetes and its multiple complications[1][2][3][4].

Product Specifications

CAS Number

[2420483-82-3]

Product Name Alternative

Polyethylene glycol loxenatide; PEX 168

UNSPSC

12352209

Target

Akt; AMPK; Apoptosis; Autophagy; GCGR; Interleukin Related; PI3K; Reactive Oxygen Species (ROS) ; Sirtuin

Type

Peptides

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/pegloxenatide.html

Purity

90.00

Solubility

10 mM in DMSO

Smiles

[PEGn-H-{D-Ala}-EGTFTSDLSKQ-{Nle}-EEEAVRLFIEWLKQGGPSSGAPPPC-NH2]

Molecular Formula

(C2H4O) n (C2H4O) nC206H317N55O67S

References & Citations

[1]Wang J, et al. Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study. Br J Clin Pharmacol. 2019 Dec;85 (12) :2714-2720.|[2]Li XY, et al. Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity. Eur Rev Med Pharmacol Sci. 2022 Nov;26 (21) :7996-8003.|[3]Zhang Y, et al. Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice. Front Pharmacol. 2021 Dec 6;12:781856.|[4]Ding Z, et al. Polyethylene Glycol Loxenatide Accelerates Diabetic Wound Healing by Downregulating Systemic Inflammation and Improving Endothelial Progenitor Cell Functions. Int J Mol Sci. 2025 Mar 6;26 (5) :2367.